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Abstract
Epigenetic changes of stromal-epithelial interactions are of key importance in the regulation of colorectal carcinoma (CRC)
cells and morphologically normal, but genetically and epigenetically altered epithelium in normal adjacent tumor (NAT)
areas. Here we demonstrated retained protein expression of well-known Wnt inhibitor, secreted frizzled-related protein 1
(SFRP1) in stromal myofibroblasts and decreasing epithelial expression from NAT tissues towards the tumor. SFRP1 was
unmethylated in laser microdissected myofibroblasts and partially hypermethylated in epithelial cells in these areas. In
contrast, we found epigenetically silenced myofibroblast-derived SFRP1 in CRC stroma. Our results suggest that the
myofibroblast-derived SFRP1 protein might be a paracrine inhibitor of epithelial proliferation in NAT areas and loss of this
signal may support tumor proliferation in CRC.
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Introduction
Communication between the epithelial and stromal compart-
ments is fundamental in the modulation of normal epithelial
homeostasis which becomes dysregulated during carcinogenesis
due to genetic and epigenetic alterations [1]. Regarding these
compartments myofibroblasts (a-SMA+, fibroblast-like cells) rep-
resent ultimate members of the information flow [2]. Myofibro-
blasts become primarily mesenchymal elements during the
development of colorectal cancer (CRC) and may play a crucial
role in the process of field cancerization [3–5]. The theory of field
cancerization describes the formation of a genetically and
epigenetically altered, but histologically normal field around the
primary tumor [6–8]. These genetic and epigenetic changes could
contribute to the altered epithelial homeostasis, characterized by
increased cell proliferation and predispose to the development of
cancer in morphologically normal adjacent tumor (NAT) areas
[9]. In some cases, between tumoral and NAT areas, a transitional
area (TA) was identified, which displayed a different degree of
dysplasia (i.e. altered crypt morphology, elongation, pseudostrat-
ification, loss of cell polarity and nuclear polymorphism). Although
several studies have already described molecular abnormalities in
association with field cancerization in epithelial tumors including
CRC, the exact role of stroma in this process is still unclear [3,10].
Here, we aim to examine the potential role of stroma-derived Wnt
inhibitor secreted frizzled-related protein 1 (SFRP1) in CRC field
cancerization.
SFRP1 inhibits proliferation and induces apoptosis by directly
binding to Wnt-1 and Wnt-5 ligands via preventing the activation
of Wnt receptors (i.e. Frizzled receptors (FRZ) and low-density
lipoprotein receptor-related protein-5 and 6 (LRP-5, LRP-6)) [11].
This system is dysregulated in around 90% of sporadic CRC
patients due to aberrant canonical Wnt signaling, including
mutation of cytoplasmic b-catenin degradation complex (DC)
proteins, such as Adenomatous Polyposis Coli (APC) and Axin
[12–14]. In 5% of CRC cases, b-catenin is mutated and does not
undergo proteasomal degradation via failed phosphorylation by
GSK3b (member of DC) [15]. Mutation of the Wnt pathway
results in inappropriate nuclear b-catenin migration, accumulation
and T-cell factor (TCF)/lymphocyte enhanced factor (LEF)
activation [11,13]. This irregular TCF/LEF activation is inde-
pendent of Wnt receptor activation; however, changes in the
homeostasis of cell lines bearing an APC mutation as a result of the
effect of different Wnt inhibitors have been described [12,16,17].
Based on the methylation analysis of macrodissected samples, it
has been described that in colorectal carcinogenesis SFRP1
promoter is epigenetically silenced [12,18–20].
PLOS ONE | www.plosone.org 1 November 2014 | Volume 9 | Issue 11 | e106143In this study, we aim to examine the protein expression and
methylation patterns of myofibroblast-derived SFRP1 in NAT
and CRC tissues, and to demonstrate the effect of SFRP1 protein
on HCT116 CRC cell line as a potential model of paracrine
(stromal) inhibition of the Wnt pathway in colorectal carcinoma.
Materials and Methods
Ethics statement
The study was conducted according to the declaration of
Helsinki and approved by Semmelweis University Ethics Com-
mittee and the governmental Regional and Institutional Commit-
tee of Science and Research Ethics (TUKEB), Nr:69/2008).
Written informed consent was obtained from all patients included
in the study.
mRNA microarray analysis of biopsy and laser
microdissected stroma samples
Endoscopically obtained biopsy samples from CRC (stage II,
moderately differentiated tumors from sigmoid colon and rectum;
n=49) areas and paired histologically normal colonic mucosa
(n=49) were taken during routine colonoscopy and stored in
RNALater Reagent (Qiagen Inc, Germantown, US) at 280uC
until further processing. Total RNA was extracted and Affymetrix
microarray analysis was performed as described before [21]. In the
laser capture microdissection study, surgically removed NAT
(n=6) and CRC (n=6) samples were used, which were embedded
in TissueTek OCT compound (Sakura Finetek, Japan). Series of
6 mm sections were mounted onto PALM Membrane Slide 1.0
PEN (Carl Zeiss, Bernried, Germany) at 220uC and were stored
at 280uC. Slides were fixated in 70% and absolute ethanol, then
stained with cresyl violet acetate (Sigma-Aldrich, St. Louis, USA).
Cells were collected from the stromal section in 5 biological
replicates using the PALM Microbeam system (PALM, Bernried,
Germany). The microarray experiment was performed as previ-
ously described [22]. All .cel files are available at GEO (Gene
Expression Omnibus, http://www.ncbi.nlm.nih.gov/geo/) under
access number: GSE4183 and GSE37364.
Cell culture, proliferation and apoptosis assays
Human CRC cell line HCT116 (from Istva ´n Peta ´k M.D.,
Ph.D., 1st Department of Pathology and Experimental Cancer
Research, Semmelweis University, Budapest, Hungary) were
cultured in DMEM (Sigma-Aldrich, Irvine, UK) supplemented
with L-glutamine, 10% fetal bovine serum (FBS, Sigma-Aldrich,
Irvine, UK) and 1% penicillin-streptomycin mixture (Sigma-
Aldrich, Irvine, UK), then grown at 37uC in an atmosphere of 5%
CO2 and 95% humidity.
For the assays, cells were seeded at a density of 70,000 cells/cm
2
in collagen-treated 24-well culture plates (Greiner Bio One,
Frickenhausen, Germany) and treatments were carried out in
duplicate (using three wells for each concentration). Cells were
treated for 48 hours with SFRP1 full length recombinant protein
(Abcam, ab64445, Cambridge, UK) at concentrations of 0.1 mg/
ml and 1.0 mg/ml. During the treatment fetal bovine serum
deprived cultures were used to avoid the interaction with SFRP1.
The treated and control cells were harvested and fixed for
30 minutes at room temperature in 70% ethanol (220uC) and
stored at 220 uC until further analysis. DNA was extracted with
alkaline buffer (200 mM di-sodium phosphate, pH 7.8, adjusted
with 200 mM citric acid) supplemented with 100 mg/ml RNase A
(Sigma-Aldrich, Irvine, UK) followed by 10 mg/ml propidium
iodide (Sigma-Aldrich, Irvine, UK) staining and incubated for
15 minutes at room temperature. 10,000–20,000 events were
measured per sample by FACScan flow cytometer (Becton
Dickinson FACScan, CA, USA), and the analyses were performed
by Winlist software (Verity Software House).
Immunohistochemistry
For immunohistochemistry normal biopsy samples (n=20),
surgically removed CRC (n=35) and colonic tissues containing
NAT and CRC areas (n=14) were used. Samples were fixed in
formaldehyde, embedded in paraffin and 4 mm thick sections were
cut. Following deparaffinization and rehydration, microwave-
based antigen retrieval was performed in TRIS EDTA buffer
(pH 9.0) (900 W/10 minutes, then 340 W/40 minutes). SFRP1
protein expression was detected using anti-SFRP1 polyclonal
antibody (ab4193, Abcam, Cambridge, UK, 1:500 dilution) with
diaminobenzidine - hydrogen peroxidase - chromogen-substrate
system (Cytomation Liquid DAB + Substrate Chromogen System,
K3468, Dako, CA, USA). This antibody showed high specificity
against SFRP1 protein which was confirmed by Western blot
(http://www.abcam.com/sfrp1-antibody-ab4193.html). Scoring
of SFRP1 protein expression representing the intensity of the
immunohistochemical reaction (both in myofibroblasts and
epithelial cells) was made on the basis of the following criteria:
the scoring value was 22 for no reaction, 0 for weak, 1 for
moderate, and 2 for strong cytoplasmic protein expression.
To identify the stromal source of SFRP1 protein a-SMA/
SFRP1 dual fluorescent staining was used in samples that
contained NAT tissues and CRC areas as well (n=9). The slides
were incubated with anti-a-SMA (Dako, CA, USA ) 1:1 solution
with Alexa Fluor 488 (Invitrogen, Eugene, CA, USA) and anti-
SFRP1 (ab4193, Abcam, Cambridge, UK) 1:500 dilution with
Alexa Fluor 546; A11035, Invitrogen, Eugene, USA) polyclonal
antibodies. Slides were digitally archived using a Pannoramic Scan
instrument (software version 1.11.25.0, 3DHISTECH Ltd,
Budapest, Hungary), and analyzed with a digital microscope
software (Pannoramic Viewer, v. 1.11.43.0 3DHISTECH Ltd,
Budapest, Hungary). We counted 1000 a-SMA+ stromal cells in
representative regions of samples with the Marker Counter built-in
modem. Where TA was identifiable, the counted cell number was
lower (150–300) because of the limited size of these areas. One-
way ANOVA test was used for data analysis.
DNA methylation analysis of laser microdissected a-SMA
positive myofibroblasts and epithelial cells
Surgically removed stage II, moderately differentiated CRC
(n=8) and paired NAT (n=8) samples (3 slides/sample) were
snap-frozen in liquid nitrogen and stored at 280uC until further
use. 1,000 myofibroblasts/slides (6 samples; 18 slides) were
collected based on their a-SMA positivity, while epithelial cells
were readily recognizable without specific staining (H&E stain; 10
samples; 30 slides). To analyze the methylation status of the
SFRP1 gene promoter, laser capture microdissected samples were
bisulfite converted using the EZ DNA Methylation-Direct Kit
TM
(Zymo Research, Irvine, USA) according to the manufacturer’s
protocol. A region on the promoter was amplified using unbiased
BS-PCR primers that do not differentiate between methylated and
unmethylated bisulfite modified DNA. (F: 59-GGAAAGAGA-
TAAGGGGAGAAAAAGAA-39;R :5 9-ATTTCATAAATTTA-
CAAATATAATCCAAACTCC-39). These primers were de-
signed using PyroMark Assay Design software 2.0. They amplify
a region 230 bp upstream of the transcription startpoint that
contains 6 CpG sites (Figure S1). The specificity of the primers was
tested in silico by the BiSearch software.
PCR cycling and HRM were performed on a LightCycler 480
instrument (Roche, Basel, Switzerland). The 25 ml reaction mix
Myofibroblast in Field Effect
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Master Mix (Life Technologies, Carlsbad, USA), 1x ResoLight
HRM Dye (Roche, Basel, Switzerland), 200 nM forward and
reverse primers and 1 ng/well bisulfite converted DNA template.
Cycling conditions were as follows: 95uC (10 min), 95uC (30 s),
60uC (30 s) decreased by 0,5uC in every cycle, 72uC (30 s) for 10
touchdown PCR cycles followed by, 95uC (30 s), 56uC (30 s) and
72uC (30 s) in 40 PCR cycles. On completion of the PCR thermal
cycling, for the HRM analysis the samples were denatured at 95uC
for 1 min, cooled down to 40uC and held for 1 min, then
continuously warmed up to 95uC at a rate of 0.03uC/second
during the melting curve fluorescence acquisition. For calibration
of the analysis, 0% and a 100% artificially methylated control
DNA samples were used (EpiTect PCR Control DNA Set,
Qiagen, Hilden, Germany). To identify characteristic melting
profiles of DNA products the LightCycler 480 Instrument Tm
Calling analysis software Module was used.
Results
Reduced stromal SFRP1 mRNA expression in CRC
compared to NAT
Whole biopsy (macrodissected) samples from NAT and CRC
regions were compared. Macrodissected NAT samples showed
significantly (P,0.001) higher SFRP1 mRNA expression than
CRC samples (Figure 1/A). Using laser microdissected tissue
compartments, higher (although not statistically significant)
SFRP1 mRNA expressions were found in the NAT epithelium
compared to CRC epithelium (Figure 1/B). However, a signifi-
cant (P,0.001) difference was observed in the expression of
Figure 1. Gene expression of SFRP1 in epithelium and stroma of NAT and CRC samples (202036_s_at and 2020367_s_at transcripts).
According to normalized log2 fluorescence intensities, biopsy samples from NAT showed high SFRP1 expression, which was significantly (P,0.001)
reduced in CRC samples (A). In epithelial cells only weak SFRP1 expression was detected both in NAT and CRC (B). In stroma SFRP1 expression was
significantly increased (C). In this area a different scale was applied for data visualization.
doi:10.1371/journal.pone.0106143.g001
Myofibroblast in Field Effect
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stromal samples from NAT and CRC. The average gene
expression values in CRC was one-third (0.38 and 0.36
respectively) of the average expression values observed in NAT
samples (Figure 1/C, Table 1). Abnormal Wnt signaling in
parallel with reduced SFRP1 was analyzed with Affymetrix whole
genome microarrays. Based on 38 normal and 38 CRC samples
(GSE37364), genes with significantly different (logFC .|2|, p,
0.001) expression levels in the tumors with reduced SFRP1
expression compared to healthy controls were listed in Table S1.
Table 1. Summary of DNA methylation, mRNA and protein expression changes of SFRP1 gene and protein in the stromal
compartment.
analyzed cells NAT Tumor P
mRNA expression stroma (LCM) logFCCRC-N=22.23 ,0.001
n=38 n=38
DNA methylation a-SMA myofibroblasts (LCM) 0% 60% n.a.
n=3/3 n=3/3
protein expression a-SMA+ SFRP1+/a-SMA cells (LCM) 85.37%612.6% 27.65%618.2% ,0.001
n=9/9 n=9/9
LCM: laser capture microdissection.
doi:10.1371/journal.pone.0106143.t001
Figure 2. SFRP1 protein expression in a-SMA+ myofibroblasts in NAT, TA and CRC areas in representative photomicrographs. SFRP1
protein expression (red immunofluorescent staining) in whole slide (A) which includes NAT (white arrow), TA (yellow arrow) and CRC (red arrow).
Both in NAT region (in 9/9 cases; B) and TA (in 4/9 cases; C) a-SMA+ myofibroblasts (E, F) showed retained SFRP1 expression (85.73612.61%) (B, C;
merged pictures: H, I). Around most CRC glands a-SMA+ myofibroblasts (green immunofluorescent staining; G) showed reduced (P,0.001) SFRP1
expression (27.65%618.27%; in 9/9 cases) (D; merged picture: J).
doi:10.1371/journal.pone.0106143.g002
Myofibroblast in Field Effect
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normal, NAT, TA and CRC
Strong stromal SFRP1 protein expression (score +2) was found
in normal, NAT and TA tissues, which localized mainly in the
pericryptal region. These stromal SFRP1+ cells were identified as
a-SMA+ myofibroblasts in NAT and in TA by dual fluorescent
immunohistochemistry. Both a-SMA and SFRP1 showed strong
(score +2) or moderate (score +1), diffuse, cytoplasmic staining in
the elongated stromal cells. In NAT regions (9/9 cases) pericryptal
a-SMA+ cells showed strong SFRP1 protein expression
(85.73612.61%; all a-SMA and SFRP1 double positive cells/all
a-SMA positive cells in stroma; Figure 2/B, E, H, Table 1).
Interestingly pericryptal a-SMA+ myofibroblasts retained strong
or moderate SFRP1 protein expression in TAs (this area was
identifiable in 4/9 cases), but the frequency of a-SMA/SFRP1
double positve cells was lower (72.3262.32%) than in NAT tissues
(Figure 2/C, F, I). In most of the analyzed CRC samples
heterogeneous SFRP1 expression was detected. The number of
a-SMA+ cells increased significantly, but the SFRP1 protein
expression was significantly reduced (27.65%618.27%) in repre-
sentative tumoral areas (in 9/9 cases) as compared to NAT
(Figure 2/D, G, J, Table 1).
In normal samples epithelial SFRP1 expression was moderate
(score: +1), lower than it was found in myofibroblasts (score: +2).
Decreased SFRP1expression was observed in 57.14% of NAT
samples (8 of 14 samples) in crypts which localized closely to the
tumor (Figure 3/B) and TAs (Figure 3/C). Parallel with the
disappearance of epithelial SFRP1 protein expression, subepithe-
lial myofibroblasts showed retained protein expression in these
areas (Figure 3/B, C). NAT regions which localized more distantly
from CRC showed similar SFRP1 protein expression patterns
than normal samples (Figure 3/A). Decreased epithelial SFRP1
protein expression (score: 0) was detected in 71.42% of CRC
samples (34 of 14+35 samples).
SFRP1 recombinant protein induces apoptosis in HCT116
cells
We analyzed the apoptotic effect of SFRP1 recombinant protein
in HCT116 (APC wild type, b-catenin mutant) cells by flow
cytometry. As the anti-proliferative and apoptotic effect of SFRP1
is well-known [12,23], we examined these functions of SFRP1 at
low concentrations (exogenously administered recombinant hu-
man SFRP1 (rhSFRP1; Abcam, Cambridge, UK); 0.1 mg/ml and
1.0 mg/ml) as a potential model of paracrine signaling. Compar-
ative analysis of treated versus non-treated specimens showed
measurable (both not statistically significant) increase of apoptosis
in a dose-dependent manner (control: 10.6660.7; 0.1 mg/ml:
12.2960.88; 1.0 mg/ml: 16.1361.68) as measured 48 hours after
a single dose of rhSFRP1 protein (Figure S2).
SFRP1 promoter hypermethylation in the NAT area and
CRC
The methylation status of a-SMA immunopositive stromal
myofibroblasts was examined in laser microdissected cells from
NAT and CRC samples. The BS-PCR products of 100%
methylated control with a higher melting temperature (melting
peak: 79.6uC) and unmethylated control with a lower melting
temperature (melt peak: 77.1uC) (Figure 4/A) were used. Myofi-
broblasts from NAT showed only one melting peak in the
unmethylated temperature range, while myofibroblasts from CRC
had an additional peak at higher temperature indicating a partially
hypermethylated status of SFRP1 promoter in CRC (Figure 4/B,
Table 1). Double peaks on the melting temperature (Tm) curves of
CRC samples denoted their heterogeneity considering their
methylation status, which was probably due to the presence of
Figure 3. Change of epithelial SFRP1 protein expression with relative distance to the tumor in representative photomicrographs.
The expression of SFRP1 protein is almost equivalent in the epithelial layer and in the subepithelial myofibroblasts in normal areas (A). In NAT areas
which were localized near the tumor (B) and TA (C) the epithelium showed decreased SFRP1 protein expression, while the subepithelial
myofibroblasts retained their SFRP1 protein expression (red arrows). In high-grade dysplasia both the epithelial and the myofibroblast-derived
SFRP1 protein expression significantly decreased (D).
doi:10.1371/journal.pone.0106143.g003
Myofibroblast in Field Effect
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promoters. Decreased epithelial SFRP1 protein expressions were
found in crypts of most NAT samples which localized closely to the
tumor. This decreased protein expression was related to epigenetic
silencing of SFRP1 gene. Partially SFRP1 promoter hypermethy-
lation was found in morphologically normal gland epithelium in
40% (2 of 5 samples) of NAT samples (Figure S3).
Discussion
Wnt signaling is a major regulator of a variety of cellular
processes during embryonic development and promotes tissue
homeostasis in the adult. Wnts are secreted lipid-modified
glycoproteins regulating a wide range of cellular behavior
including differentiation, proliferation, migration, survival, polar-
ity and stem cell self-renewal [24]. Altered Wnt signaling may
contribute to the development of several disorders including
cancer [25]. The canonical/b-catenin pathway is the most
extensively studied Wnt signaling mechanism, which is triggered
by Wnt binding to a member of the Frizzled receptor family and
co-receptors (LRP5 or LRP6) [26]. This results in the recruitment
of Dishevelled to Frizzled and Axin to phosphorylated LRP5/6,
leading to the dissociation of a b-catenin degradation complex. In
the absence of Wnt this complex mediates the sequential
phosphorylation of b-catenin, causing its ubiquitination and
proteasomal degradation. Wnt stimulation allows the accumula-
tion of hypophosphorylated b-catenin in the cytosol and its
translocation into the nucleus, where it binds to TCF/LEF and
promotes the expression of Wnt/b-catenin target genes [26].
Constitutive activation of this pathway is commonly present in
many types of cancer [24,25]. Non-canonical Wnt-signaling
pathways (planar cell polarity or increased intracellular calcium
concentration) are transduced by Frizzleds and/or other Wnt
receptors or co-receptors [26,27]. Several non-canonical Wnt
signaling mechanisms have been reported to inhibit the b-catenin
pathway by decreasing b-catenin/TCF association with DNA or
increasing b-catenin turnover [28–30].
SFRPs comprise a family of five proteins in mammals that were
first identified as antagonists of the Wnt/b-catenin pathway during
embryonic development [31–33]. SFRPs possess a remarkable
range of biological activities, including tumor suppression [11,34].
This is also strengthened by epigenetic silencing of SFRP gene
expression in a wide variety of cancers [35,36], and supported by
the observation that restoration of expression is suppressive of the
tumor phenotype [37,38]. By contrast, SFRP overexpression has
been observed in some of the same malignancies [39–41].
Consistent with this duality, SFRP1 showed a biphasic effect on
b-catenin stabilization elicited by Wingless, increasing b-catenin
protein levels at low SFRP1 concentrations, but inhibiting it at
high concentrations [42]. In different cellular contexts, SFRP1 has
been shown either to increase or decrease b-catenin stabilization
[43,44]. Furthermore, another study suggested that SFRP1 could
stimulate the Wnt/calcium pathway via Frizzled-2 independently
of endogenous Wnts [45].
Regarding field cancerization, methylation of hMLH1,
CDKN2A/P16 and SFRP1 has been recently indicated to be
associated with malignant transition in endometrial cancer [46].
In our study, the apoptotic effect of SFRP1 protein was
demonstrated by administering low doses of rhSFRP1 on
HCT116 CRC cell line. In HCT116 cells rhSFRP1 protein
caused a measurable increase in apoptosis.
We investigated the role of SFRP1 regarding the stroma-
epithelium interaction in CRC and NAT areas. SFRP1 protein is
a well-known intercellular inhibitor of Wnt pathway which
regulates the epithelial proliferation as autocrine and/or paracrine
signal [12,23]. We identified a-SMA+ myofibroblasts as the main
source of stromal SFRP1 protein in NAT regions, in parallel with
unmethylated SFRP1 promoter sequences. We also observed
moderate to strong SFRP1 protein expression in a-SMA+
myofibroblasts in TA, which was characterized by altered crypt
morphology (e.g. elongation, pseudostratification, loss of cell
polarity and nuclear polymorphism). On the contrary, epigenetic
silencing of epithelial SFRP1 appeared in both areas and this
could serve as an early sign of field cancerization.
According to our hypothesis, in these areas field cancerization
caused epithelial proliferation, which was partly inhibited by the
less dysregulated stroma, indicated by the lower frequency of
SFRP1 hypermethylation in myofibroblasts. Thus, decreased
epithelial SFRP1 protein expression may partly be replaced by
stromal sources (i.e. by a-SMA+ myofibroblasts). In contrast to the
DNA repair gene O6-methylguanine-DNA methyltransferase
(MGMT) [10], which has been found to be methylated in the
macroscopic field of some CRCs, in our study epithelial SFRP1
Figure 4. Promoter hypermethylation of SFRP1 gene in BS-PCR
HRM. SFRP1 is hypermethylated in a-SMA positive myofibro-
blasts in CRC. A: Melting peaks of SFRP1 BS-PCR products. Melting
temperature (Tm) of 0% methylated standard sample was 77.1uC, while
Tm of 100% methylated standard was 79.6uC. B: There was only one
unmethylated melting peak detectable for NAT samples (green curves).
In CRC samples (red curves) an additional melting peak belonging to
hypermethylated products appeared, suggesting that a-SMA positive
myofibroblasts are heterogenous concerning SFRP1 promoter methyl-
ation.
doi:10.1371/journal.pone.0106143.g004
Myofibroblast in Field Effect
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tumor (NAT).
Although in most CRC cases stromal myofibroblasts exhibited
hypermethylation and low protein expression of SFRP1,w e
hypothesize that the remaining myofibroblasts with intact SFRP1
protein expression can decrease the proliferation rate of Wnt
mutant CRC cells.
To conclude, our present study indicates that SFRP1 protein
expression is conserved in a-SMA+ myofibroblasts and partially
disappears in the epithelium of NAT and TA. In contrast, we
found low SFRP1 immunopositivity stroma-associated myofibro-
blasts in CRC. Both epithelial and myofibroblast-derived SFRP1
expression is under epigenetic regulation. We presume that the
paracrine, anti-proliferative effect of myofibroblast-derived SFRP1
may inhibit field cancerization in NAT and TA areas, and so
cancer-associated myofibroblasts may support the uncontrolled
tumor cell proliferation by an epigenetically silenced Wnt
inhibitory signal.
Supporting Information
Figure S1 Position of the BS-PCR product (black) on the
SFRP1 gene promoter. The transcript of SFRP1 is represented
by the blue line; CpG sites are red lines. Figure modified from
UCSC genome browser (Human, GRCh37/hg19 Assembly).
(TIF)
Figure S2 Apoptotic effect of recombinant SFRP1 pro-
tein on HCT116 cell line. rhSFRP1 protein caused measurable
(both not statistically significant) increase in apoptosis (48 hours
after a single dose).
(TIF)
Figure S3 Promoter hypermethylation of SFRP1 in
epithelial cells in NAT area. A: Melting peaks of SFRP1
BS-PCR products. Melting temperature of the 0% methylated
standard sample was 77uC, while Tm of the 100% methylated
standard was 79.5uC. B: SFRP1 was hypermethylated in 2/5
epithelial cells (40%) in NAT area (red line) indicated by their
melting peaks at higher temperature.
(TIF)
Table S1 Genes with significantly different (logFC .|2|, p,
0.001) expression levels in tumors with reduced SFRP1 expression
compared to healthy controls.
(DOCX)
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